OncoMatch/Clinical Trials/NCT03838926
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
Is NCT03838926 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Trichostatin A for relapsed or refractory hematologic malignancies.
Treatment: Trichostatin A — The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Cardiac function
Impaired cardiac function or conduction defect [excluded]
Impaired cardiac function or conduction defect
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Vanda Investigational Site · Washington D.C., District of Columbia
- Vanda Investigational Site · Lafayette, Indiana
- Vanda Investigational Site · Hackensack, New Jersey
- Vanda Investigational Site · Seattle, Washington
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03838926 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify